Thymosin alpha-1
Thymalfasin
Thymosin alpha-1 is an immunomodulatory peptide studied in specific disease settings. A generic “immune boost” is not established.
Peptipedia explains research and prescribing information. It does not replace medical advice and is not an invitation to use a substance.
Research areas
Evidence matrix
- Molecular identity
- Confirmed
Thymosin alpha-1/thymalfasin is the defined peptide used in the cited sepsis trials. Unspecified or compounded products are not thereby confirmed.
- Human research
- Strong
- Replication
- Single research group
- Clinical endpoints
- Hard patient-relevant outcomes
- Safety
- Limited characterization
- Approval
- No documented approval
The dimensions are presented separately and are not combined into an overall score.
What the source shows
The large double-blind TESTS phase 3 trial, with 1,106 randomized adults with sepsis, found no clear benefit on the primary endpoint of 28-day all-cause mortality.
- The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trialHuman study2025
Wu J et al.; TESTS study collaborator group
Accessed:
Research gaps
- ·Sepsis studies cannot be extrapolated to healthy people or other indications. Country-specific authorizations are not presented as EU or US approvals without suitable original documents.
- ·Short profile: not a complete benefit–risk assessment. Unlisted contraindications and interactions are not adequately established in this profile; missing information does not establish safety.
Mechanism
Research examines changes in immune responses; this is not general enhancement of immune performance in healthy people.
- The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trialHuman study2013
Wu J et al.
Accessed:
Study protocols
No sufficiently supported, exactly citable study protocols are available.
Calculator
Arithmetic based only on your entries. Not a dose or use recommendation.
Reported adverse effects
- ·Prespecified safety outcomes did not differ statistically in TESTS; that does not establish safety outside the studied sepsis population. Rare and long-term risks remain inadequately characterized.
Contraindications and warnings
No reviewed information on this point has been recorded here yet. This does not mean there are no risks or contraindications.
Interactions
No reviewed information on this point has been recorded here yet. This does not mean there are no risks or contraindications.
Research gaps
- ·Sepsis studies cannot be extrapolated to healthy people or other indications. Country-specific authorizations are not presented as EU or US approvals without suitable original documents.
- ·Short profile: not a complete benefit–risk assessment. Unlisted contraindications and interactions are not adequately established in this profile; missing information does not establish safety.
- The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trialHuman study2013
Wu J et al.
Accessed:
Sources
Sources checked: · Version 3
- The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trialHuman study2013
Wu J et al.
Accessed:
- The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trialHuman study2025
Wu J et al.; TESTS study collaborator group
Accessed: